(pressebox) Heidelberg, Germany, 19.10.2009, Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology. Under the terms of the agreement, Graffinity [...]
Tag Archive > High Throughput Screening
Roche’s xCELLigence System and FuGENE® HD Transfection Reagent minimize cytotoxic effects in the detection of bax-induced apoptosis
(pressebox) Penzberg, 17.09.2009, Transfection is a way to transiently or permanently deliver nucleic acids into eukaryotic cells to study functional effects in response to altered gene expression and for protein production. In a recent study (1) the xCELLigence System for cellular analysis from Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) was used to compare [...]
TIBCO Spotfire stattet Spitzenforschung im Deutschen Krebsforschungszentrum aus
(pressebox) Somerville, München, 13.07.2009, Das Deutsche Krebsforschungszentrum (DKFZ) in Heidelberg nutzt für unterschiedliche Forschungsaufgaben die Enterprise Analytics-Plattform von TIBCO Spotfire, Inc. (NASDAQ: TIBX). In den einzelnen Projekten werden Mechanismen der Krebsentstehung erforscht, maßgeschneiderte Wirkstoffe entwickelt und weitere durch Infektionen hervorgerufene Krebsformen gesucht. Dr. Mark Demesmaeker, European Manager Solution Consulting bei TIBCO Spotfire: ?Dies unterstreicht die [...]
Novation and Cancer Therapeutics establish collaboration for the discovery and development of new cancer therapies
(pressebox) New Westminster, B.C., 15.06.2009, Novation Pharmaceuticals Inc, Vancouver, Canada and Cancer Therapeutics CRC Pty Ltd Melbourne, Australia, (CTx) today announced a joint collaboration to identify potent small-molecule compounds for two very important but highly intractable oncology targets, c-myc and hSSB1. The collaboration will involve the use of Novation’s novel Quest drug discovery platform technology [...]
Nanion’s SyncroPatch 96 validated with various targets and cells
(pressebox) München, 14.04.2009, The SyncroPatch 96, a high quality, high throughput patch clamp ion channel screening platform, shows impressive results with a wide variety of ion channels targets and cell lines. The SyncroPatch 96 was displayed for the first time at the Biophysical Society Meeting in Boston, raising great interest within the pharma industry because [...]
CyBio and Axxam Develop a New System for High Throughput Screening
(pressebox) Jena/Milan, 20.03.2009, CyBio AG and Axxam SpA announce that they have developed, installed and fully validated a new state-of-the-art screening station to be used by Axxam in running hit discovery campaigns with automated luminescence and fluorescence screening systems. CyBio AG is a worldwide leading life science company. As an innovative technology provider CyBio develops, [...]
Analytik Jena prognostiziert für Geschäftsjahr 2008/2009 zweistelliges Wachstum im Umsatz und im Ergebnis
(pressebox) Jena, 19.03.2009, Anlässlich der heute stattfindenden ordentlichen Hauptversammlung der Analytik Jena AG (ISIN DE0005213508) äußert sich der Vorstand zu den Zielstellungen für das laufende Geschäftsjahr. Die Prognose beinhaltet auch Ergebnisbeiträge der ab März zu konsolidierenden CyBio AG, die ausgeglichen bzw. leicht positiv erwartet werden. Die Gesellschaft rechnet im aktuellen Geschäftsjahr mit einer Steigerung des [...]
Scienion receives ISO 9001:2008 certification
(pressebox) Dortmund, Germany, 18.02.2009, Scienion AG, Dortmund, today announced the DIN EN ISO 9001:2008 certification for the development, manufacture and sales of dispensing systems and microarrays. Scienion is one of the first biotech companies that have been certified according to the latest revision of the world’s most widely used standard for quality management systems. "The [...]
